{"transactions":[{"id":1064,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-02T21:31:14.000Z","date":"2026-08-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":1692,"price":241.39,"value":408431.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."}],"balance_after":6923,"source":{"system":"sec-edgar","filing":"0001161662-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000116166226000008/edgardoc.xml","form_type":"4"}},{"id":1063,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-02T21:31:14.000Z","date":"2026-08-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":14,"price":244.6443,"value":3425.0202,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."}],"balance_after":8615,"source":{"system":"sec-edgar","filing":"0001161662-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000116166226000008/edgardoc.xml","form_type":"4"}},{"id":693357,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-08-07T21:33:47.000Z","date":"2026-08-05","kind":"grant","planned":false,"acquired":true,"shares":1605,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Shares beneficially owned by NORBERT G. RIEDEL 2023 TRUST, an entity owned and controlled by the reporting person and his immediate family."}],"balance_after":8629,"source":{"system":"sec-edgar","filing":"0001161662-26-000005","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000116166226000005/edgardoc.xml","form_type":"4"}},{"id":697629,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-08-04T20:56:34.000Z","date":"2026-07-31","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date.  If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date.  If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date.  If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-26-025696","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774926025696/rdgdoc.xml","form_type":"4"}},{"id":803106,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-04-22T20:40:35.000Z","date":"2026-04-21","kind":"exercise","planned":false,"acquired":false,"shares":19655,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":8.61,"exercise_date":"2022-05-03","expiration_date":"2031-05-02","underlying":"Common Stock","underlying_shares":19655},"source":{"system":"sec-edgar","filing":"0001437749-26-013041","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774926013041/rdgdoc.xml","form_type":"4"}},{"id":803105,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-04-22T20:40:35.000Z","date":"2026-04-21","kind":"exercise","planned":false,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":7.31,"exercise_date":"2020-02-20","expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001437749-26-013041","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774926013041/rdgdoc.xml","form_type":"4"}},{"id":803104,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-04-22T20:40:35.000Z","date":"2026-04-21","kind":"exercise","planned":false,"acquired":true,"shares":19655,"price":8.61,"value":169229.55,"ownership":{"direct":true},"balance_after":67155,"source":{"system":"sec-edgar","filing":"0001437749-26-013041","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774926013041/rdgdoc.xml","form_type":"4"}},{"id":803103,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-04-22T20:40:35.000Z","date":"2026-04-21","kind":"exercise","planned":false,"acquired":true,"shares":12500,"price":7.31,"value":91375.0,"ownership":{"direct":true},"balance_after":47500,"source":{"system":"sec-edgar","filing":"0001437749-26-013041","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774926013041/rdgdoc.xml","form_type":"4"}},{"id":874920,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-03-02T22:36:59.000Z","date":"2026-02-27","kind":"exercise","planned":false,"acquired":false,"shares":3415,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This non-qualified stock option was granted on August 11, 2016 and vested over a period of one year from September 1, 2016. The options were fully vested as of August 1, 2017."}],"balance_after":0,"derivative":{"exercise_price":138.08,"expiration_date":"2026-08-10","underlying":"Ordinary Shares","underlying_shares":3415},"source":{"system":"sec-edgar","filing":"0001161662-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000116166226000002/edgardoc.xml","form_type":"4"}},{"id":874919,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-03-02T22:36:59.000Z","date":"2026-02-27","kind":"sale","planned":false,"acquired":false,"shares":3415,"price":192,"value":655680.0,"ownership":{"direct":true},"balance_after":7024,"source":{"system":"sec-edgar","filing":"0001161662-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000116166226000002/edgardoc.xml","form_type":"4"}},{"id":874918,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-03-02T22:36:59.000Z","date":"2026-02-27","kind":"exercise","planned":false,"acquired":true,"shares":3415,"price":138.08,"value":471543.2,"ownership":{"direct":true},"balance_after":10439,"source":{"system":"sec-edgar","filing":"0001161662-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000116166226000002/edgardoc.xml","form_type":"4"}},{"id":918042,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-05T22:18:48.000Z","date":"2026-02-03","kind":"other","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":4.42,"exercise_date":"2025-02-13","expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001437749-26-003230","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774926003230/rdgdoc.xml","form_type":"4"}},{"id":918041,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-05T22:18:48.000Z","date":"2026-02-03","kind":"other","planned":false,"acquired":true,"shares":30000,"price":4.42,"value":132600.0,"ownership":{"direct":true},"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001437749-26-003230","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774926003230/rdgdoc.xml","form_type":"4"}},{"id":939482,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-01-14T23:09:09.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":7757,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting."}],"balance_after":294253,"derivative":{"underlying":"Common Stock","underlying_shares":7757},"source":{"system":"sec-edgar","filing":"0001437749-26-001301","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774926001301/rdgdoc.xml","form_type":"4"}},{"id":939481,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-01-14T23:09:09.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":12196,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on January 12, 2027."}],"balance_after":286496,"derivative":{"exercise_price":15.47,"expiration_date":"2036-01-11","underlying":"Common Stock","underlying_shares":12196},"source":{"system":"sec-edgar","filing":"0001437749-26-001301","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774926001301/rdgdoc.xml","form_type":"4"}},{"id":1070583,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:37:38.000Z","date":"2025-08-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":1805,"price":111.2498,"value":200805.889,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Shares beneficially owned by NORBERT G. RIEDEL 2023 TRUST, an entity owned and controlled by the reporting person and his immediate family."}],"balance_after":7024,"source":{"system":"sec-edgar","filing":"0001765581-25-000082","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558125000082/edgardoc.xml","form_type":"4"}},{"id":1070582,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:37:38.000Z","date":"2025-08-07","kind":"grant","planned":false,"acquired":true,"shares":3507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026."}],"balance_after":8829,"source":{"system":"sec-edgar","filing":"0001765581-25-000082","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558125000082/edgardoc.xml","form_type":"4"}},{"id":1311401,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-06T21:22:21.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.47,"exercise_date":"2024-02-20","expiration_date":"2033-02-19","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001437749-25-000466","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774925000466/rdgdoc.xml","form_type":"4"}},{"id":1311400,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-06T21:22:21.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.78,"exercise_date":"2023-02-07","expiration_date":"2032-02-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001437749-25-000466","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774925000466/rdgdoc.xml","form_type":"4"}},{"id":1311399,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-06T21:22:21.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":false,"shares":27400,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.58,"exercise_date":"2021-03-12","expiration_date":"2030-03-12","underlying":"Common Stock","underlying_shares":27400},"source":{"system":"sec-edgar","filing":"0001437749-25-000466","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774925000466/rdgdoc.xml","form_type":"4"}},{"id":1311398,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-01-06T21:22:21.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":3.47,"value":86750.0,"ownership":{"direct":true},"balance_after":162145,"source":{"system":"sec-edgar","filing":"0001437749-25-000466","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774925000466/rdgdoc.xml","form_type":"4"}},{"id":1311397,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-01-06T21:22:21.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":3.78,"value":189000.0,"ownership":{"direct":true},"balance_after":137145,"source":{"system":"sec-edgar","filing":"0001437749-25-000466","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774925000466/rdgdoc.xml","form_type":"4"}},{"id":1311396,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-01-06T21:22:21.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":true,"shares":27400,"price":3.58,"value":98092.0,"ownership":{"direct":true},"balance_after":87145,"source":{"system":"sec-edgar","filing":"0001437749-25-000466","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774925000466/rdgdoc.xml","form_type":"4"}},{"id":1311395,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-06T21:20:11.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest equally on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on January 3, 2026."}],"balance_after":25000,"derivative":{"exercise_price":13,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001437749-25-000462","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774925000462/rdgdoc.xml","form_type":"4"}},{"id":1439787,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-08-06T22:41:22.000Z","date":"2024-08-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":1484,"price":111.35,"value":165243.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."}],"balance_after":5322,"source":{"system":"sec-edgar","filing":"0001765581-24-000077","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558124000077/edgardoc.xml","form_type":"4"}},{"id":1439786,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-08-06T22:41:22.000Z","date":"2024-08-02","kind":"grant","planned":false,"acquired":true,"shares":3731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 25, 2025."}],"balance_after":6806,"source":{"system":"sec-edgar","filing":"0001765581-24-000077","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558124000077/edgardoc.xml","form_type":"4"}},{"id":1441112,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-05T20:24:59.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":95242,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":95242},"source":{"system":"sec-edgar","filing":"0000950170-24-090806","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000095017024090806/ownership.xml","form_type":"4"}},{"id":1441111,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:24:59.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10461,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are represented by restricted stock units (\"RSUs\"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares are represented by restricted stock units (\"RSUs\"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-090806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000095017024090806/ownership.xml","form_type":"4"}},{"id":1441110,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:24:59.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":46092,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."}],"balance_after":10461,"source":{"system":"sec-edgar","filing":"0000950170-24-090806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000095017024090806/ownership.xml","form_type":"4"}},{"id":1487269,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T20:30:57.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":10461,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company."}],"balance_after":56553,"source":{"system":"sec-edgar","filing":"0000950170-24-070725","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000095017024070725/ownership.xml","form_type":"4"}},{"id":1641367,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true}}],"security":"Stock Option (Right to buy)","published_at":"2024-02-15T21:15:51.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 13, 2025."}],"balance_after":164555,"derivative":{"exercise_price":4.42,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001437749-24-004358","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000143774924004358/rdgdoc.xml","form_type":"4"}},{"id":1807556,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-08-15T21:58:30.000Z","date":"2023-08-14","kind":"sale","planned":false,"acquired":false,"shares":1241,"price":138.1581,"value":171454.2021,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.68 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":13705,"source":{"system":"sec-edgar","filing":"0001765581-23-000088","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558123000088/edgardoc.xml","form_type":"4"}},{"id":1807555,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-08-15T21:58:30.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":3075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024."}],"balance_after":14946,"source":{"system":"sec-edgar","filing":"0001765581-23-000088","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558123000088/edgardoc.xml","form_type":"4"}},{"id":1860991,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T20:15:13.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":13780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date."}],"balance_after":13780,"derivative":{"exercise_price":32.6,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":13780},"source":{"system":"sec-edgar","filing":"0000899243-23-015179","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000089924323015179/doc4.xml","form_type":"4"}},{"id":1860990,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T20:15:13.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":3282,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date."}],"balance_after":46092,"source":{"system":"sec-edgar","filing":"0000899243-23-015179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000089924323015179/doc4.xml","form_type":"4"}},{"id":1975007,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-03T21:10:22.000Z","date":"2023-03-03","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Option was approved by the Compensation Committee of the Board of Directors as of February 20, 2023 and approved by the full Board of Directors on March 3, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 20,2024."}],"balance_after":134555,"derivative":{"exercise_price":3.47,"expiration_date":"2033-02-19","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001493152-23-006677","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000149315223006677/ownership.xml","form_type":"4"}},{"id":2063247,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EXECUTIVE CHAIRMAN OF THE BOD"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-05T21:17:01.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":420000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest 25% on January 3, 2024, with the remaining 75% vesting in equal monthly installments over 36 months."}],"balance_after":420000,"derivative":{"exercise_price":0.36,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":420000},"source":{"system":"sec-edgar","filing":"0001415889-23-000545","document":"form4-01052023_090146.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000141588923000545/form4-01052023_090146.xml","form_type":"4"}},{"id":2191185,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-08-09T22:38:27.000Z","date":"2022-08-05","kind":"exercise","acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Option Plan. Subject to the Reporting Person's continuous service and certain additional conditions, this option vested over three years from the Vesting Commencement Date, with 1/3 that vested on the first anniversary of the Vesting Commencement Date and the remainder vested in 24 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":55.28,"expiration_date":"2023-05-08","underlying":"Ordinary Shares","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001765581-22-000096","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558122000096/edgardoc.xml","form_type":"4"}},{"id":2191184,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-08-09T22:38:27.000Z","date":"2022-08-08","kind":"sale","acquired":false,"shares":1089,"price":152.3204,"value":165876.9156,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."}],"balance_after":11871,"source":{"system":"sec-edgar","filing":"0001765581-22-000096","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558122000096/edgardoc.xml","form_type":"4"}},{"id":2191183,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-08-09T22:38:27.000Z","date":"2022-08-05","kind":"grant","acquired":true,"shares":2561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 28, 2023."}],"balance_after":12960,"source":{"system":"sec-edgar","filing":"0001765581-22-000096","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558122000096/edgardoc.xml","form_type":"4"}},{"id":2191182,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-08-09T22:38:27.000Z","date":"2022-08-05","kind":"sale","acquired":false,"shares":8000,"price":155.865,"value":1246920.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.80.00 to $156.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":10399,"source":{"system":"sec-edgar","filing":"0001765581-22-000096","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558122000096/edgardoc.xml","form_type":"4"}},{"id":2191181,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-08-09T22:38:27.000Z","date":"2022-08-05","kind":"exercise","acquired":true,"shares":8000,"price":55.28,"value":442240.0,"ownership":{"direct":true},"balance_after":18399,"source":{"system":"sec-edgar","filing":"0001765581-22-000096","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558122000096/edgardoc.xml","form_type":"4"}},{"id":2230336,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T20:49:25.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":23459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date."}],"balance_after":23459,"derivative":{"exercise_price":24.35,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":23459},"source":{"system":"sec-edgar","filing":"0000899243-22-022836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000089924322022836/doc4.xml","form_type":"4"}},{"id":2369390,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-02-28T21:34:44.000Z","date":"2022-02-07","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 7,2023."}],"balance_after":109555,"derivative":{"exercise_price":3.78,"expiration_date":"2032-02-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-005618","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000149315222005618/ownership.xml","form_type":"4"}},{"id":2442184,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-01-06T21:31:17.000Z","date":"2022-01-04","kind":"exercise","acquired":false,"shares":14270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"14,270 RSUs vested on January 4, 2022, the third anniversary of the vesting commencement date of January 4, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"14,270 RSUs vested on January 4, 2022, the third anniversary of the vesting commencement date of January 4, 2019."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14270},"source":{"system":"sec-edgar","filing":"0000899243-22-001199","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000089924322001199/doc4.xml","form_type":"4"}},{"id":2442183,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:31:17.000Z","date":"2022-01-04","kind":"exercise","acquired":true,"shares":14270,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock."}],"balance_after":42810,"source":{"system":"sec-edgar","filing":"0000899243-22-001199","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000089924322001199/doc4.xml","form_type":"4"}},{"id":2481003,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-12-08T21:16:23.000Z","date":"2021-12-06","kind":"purchase","acquired":true,"shares":100000,"price":2.23,"value":223000.0,"ownership":{"direct":false,"nature":"By Riedel 2020 Irrevocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.22 to $2.23, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001415889-21-005779","document":"form4-12082021_011216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000141588921005779/form4-12082021_011216.xml","form_type":"4"}},{"id":2482656,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-07T21:16:13.000Z","date":"2021-12-02","kind":"grant","acquired":true,"shares":475000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest 25% on December 2, 2022, with the remaining 75% vesting in equal monthly installments over 36 months."}],"balance_after":475000,"derivative":{"exercise_price":2.28,"expiration_date":"2031-12-01","underlying":"Common Stock","underlying_shares":475000},"source":{"system":"sec-edgar","filing":"0001415889-21-005740","document":"form4-12072021_011257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000141588921005740/form4-12072021_011257.xml","form_type":"4"}},{"id":2608747,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-08-10T21:38:35.000Z","date":"2021-08-06","kind":"sale","acquired":false,"shares":1306,"price":147.96,"value":193235.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."}],"balance_after":10399,"source":{"system":"sec-edgar","filing":"0001765581-21-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558121000108/edgardoc.xml","form_type":"4"}},{"id":2620272,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-08-02T22:25:23.000Z","date":"2021-07-29","kind":"grant","acquired":true,"shares":2246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 29, 2022."}],"balance_after":11705,"source":{"system":"sec-edgar","filing":"0001765581-21-000081","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558121000081/edgardoc.xml","form_type":"4"}},{"id":2670529,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-15T00:14:42.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":58003,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date."}],"balance_after":58003,"derivative":{"exercise_price":13.93,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":58003},"source":{"system":"sec-edgar","filing":"0000899243-21-023723","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000089924321023723/doc4.xml","form_type":"4"}},{"id":2703542,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2021-05-20T21:53:09.000Z","date":"2021-05-17","kind":"exercise","acquired":false,"shares":380000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vest on May 16, 2021, subject to the Reporting Person's continued service. The underlying vested shares settled on May 17, 2021, the business day immediately following May 16, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest on May 16, 2021, subject to the Reporting Person's continued service. The underlying vested shares settled on May 17, 2021, the business day immediately following May 16, 2021."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":380000},"source":{"system":"sec-edgar","filing":"0001415889-21-002619","document":"form4a-05202021_020551.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000141588921002619/form4a-05202021_020551.xml","form_type":"4/A","original_submission_date":"2021-05-19"}},{"id":2703541,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-05-20T21:53:09.000Z","date":"2021-05-17","kind":"tax_withholding","acquired":false,"shares":127274,"price":2.53,"value":322003.22,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person."}],"balance_after":615265,"source":{"system":"sec-edgar","filing":"0001415889-21-002619","document":"form4a-05202021_020551.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000141588921002619/form4a-05202021_020551.xml","form_type":"4/A","original_submission_date":"2021-05-19"}},{"id":2703540,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-05-20T21:53:09.000Z","date":"2021-05-17","kind":"exercise","acquired":true,"shares":380000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock issued to the reporting person upon settlement of the RSUs on May 17, 2021, the business day immediately following May 16, 2021, the date that the RSUs became fully vested."}],"balance_after":742539,"source":{"system":"sec-edgar","filing":"0001415889-21-002619","document":"form4a-05202021_020551.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000141588921002619/form4a-05202021_020551.xml","form_type":"4/A","original_submission_date":"2021-05-19"}},{"id":2705857,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2021-05-19T22:46:25.000Z","date":"2021-05-17","kind":"exercise","acquired":false,"shares":380000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vest on May 16, 2021, subject to the Reporting Person's continued service. The underlying vested shares settled on May 17, 2021, the business day immediately following May 16, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest on May 16, 2021, subject to the Reporting Person's continued service. The underlying vested shares settled on May 17, 2021, the business day immediately following May 16, 2021."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":380000},"source":{"system":"sec-edgar","filing":"0001415889-21-002573","document":"form4-05192021_030509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000141588921002573/form4-05192021_030509.xml","form_type":"4"}},{"id":2705856,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-05-19T22:46:25.000Z","date":"2021-05-17","kind":"tax_withholding","acquired":false,"shares":127274,"price":2.53,"value":322003.22,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person."}],"balance_after":615265,"source":{"system":"sec-edgar","filing":"0001415889-21-002573","document":"form4-05192021_030509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000141588921002573/form4-05192021_030509.xml","form_type":"4"}},{"id":2705855,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-05-19T22:46:25.000Z","date":"2021-05-17","kind":"exercise","acquired":true,"shares":380000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock issued to the reporting person upon settlement of the RSUs on May 17, 2021, the business day immediately following May 16, 2021, the date that the RSUs became fully vested."}],"balance_after":742539,"source":{"system":"sec-edgar","filing":"0001415889-21-002573","document":"form4-05192021_030509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000141588921002573/form4-05192021_030509.xml","form_type":"4"}},{"id":2727740,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-05-05T20:15:55.000Z","date":"2021-05-03","kind":"grant","acquired":true,"shares":19655,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on May 3, 2022."}],"balance_after":59555,"derivative":{"exercise_price":8.61,"expiration_date":"2031-05-03","underlying":"Common Stock","underlying_shares":19655},"source":{"system":"sec-edgar","filing":"0001493152-21-010525","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000149315221010525/ownership.xml","form_type":"4"}},{"id":2830118,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-27T00:34:03.000Z","date":"2021-02-24","kind":"grant","acquired":true,"shares":733300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest 25% on February 24, 2022, with the remaining 75% vesting in equal monthly installments over 36 months."}],"balance_after":733300,"derivative":{"exercise_price":3.8,"expiration_date":"2031-02-23","underlying":"Common Stock","underlying_shares":733300},"source":{"system":"sec-edgar","filing":"0001415889-21-001006","document":"form4-02262021_040246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000141588921001006/form4-02262021_040246.xml","form_type":"4"}},{"id":2916267,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-01-06T21:26:46.000Z","date":"2021-01-04","kind":"exercise","acquired":false,"shares":14270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"14,270 RSUs vested on January 4, 2021, the second anniversary of the vesting commencement date of January 4, 2019 (the \"Vesting Commencement Date\"), with the remainder vesting on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service relationship with the Issuer through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"14,270 RSUs vested on January 4, 2021, the second anniversary of the vesting commencement date of January 4, 2019 (the \"Vesting Commencement Date\"), with the remainder vesting on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service relationship with the Issuer through each such date."}],"balance_after":14270,"derivative":{"underlying":"Common Stock","underlying_shares":14270},"source":{"system":"sec-edgar","filing":"0000899243-21-000688","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000089924321000688/doc4.xml","form_type":"4"}},{"id":2916266,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-06T21:26:46.000Z","date":"2021-01-04","kind":"exercise","acquired":true,"shares":14270,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock."}],"balance_after":28540,"source":{"system":"sec-edgar","filing":"0000899243-21-000688","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000089924321000688/doc4.xml","form_type":"4"}},{"id":3063689,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-08-10T20:50:32.000Z","date":"2020-08-06","kind":"grant","acquired":true,"shares":6765,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan.  Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in full on July 30, 2021."}],"balance_after":6765,"derivative":{"exercise_price":127.07,"expiration_date":"2030-08-05","underlying":"Ordinary Shares","underlying_shares":6765},"source":{"system":"sec-edgar","filing":"0001765581-20-000079","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558120000079/edgardoc.xml","form_type":"4"}},{"id":3063688,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-08-10T20:50:32.000Z","date":"2020-08-07","kind":"sale","acquired":false,"shares":931,"price":125.8708,"value":117185.7148,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."}],"balance_after":9459,"source":{"system":"sec-edgar","filing":"0001765581-20-000079","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558120000079/edgardoc.xml","form_type":"4"}},{"id":3063687,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-08-10T20:50:32.000Z","date":"2020-08-06","kind":"grant","acquired":true,"shares":2705,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 30, 2021."}],"balance_after":10390,"source":{"system":"sec-edgar","filing":"0001765581-20-000079","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558120000079/edgardoc.xml","form_type":"4"}},{"id":3209196,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-03-16T20:52:50.000Z","date":"2020-03-12","kind":"grant","acquired":true,"shares":27400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on March 12, 2021."}],"balance_after":27400,"derivative":{"exercise_price":3.58,"expiration_date":"2030-03-11","underlying":"Common Stock","underlying_shares":27400},"source":{"system":"sec-edgar","filing":"0001493152-20-004053","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000149315220004053/ownership.xml","form_type":"4"}},{"id":3241515,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-28T21:34:51.000Z","date":"2020-02-26","kind":"grant","acquired":true,"shares":625000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest 25% on February 26, 2021, with the remaining 75% vesting in equal monthly installments over 36 months."}],"balance_after":625000,"derivative":{"exercise_price":3.12,"expiration_date":"2030-02-25","underlying":"Commmon Stock","underlying_shares":625000},"source":{"system":"sec-edgar","filing":"0001567619-20-005135","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000156761920005135/doc1.xml","form_type":"4"}},{"id":3311795,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-01-14T21:23:10.000Z","date":"2020-01-10","kind":"purchase","acquired":true,"shares":35000,"price":3,"value":105000.0,"ownership":{"direct":false,"nature":"by Norbert G. Riedel 2015 Family Trust"},"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001567619-20-001019","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000156761920001019/doc1.xml","form_type":"4"}},{"id":3441296,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-08-12T21:32:47.000Z","date":"2019-08-08","kind":"grant","acquired":true,"shares":4805,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan.  Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan.  Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019."}],"balance_after":4805,"derivative":{"exercise_price":137.12,"expiration_date":"2029-08-07","underlying":"Ordinary Shares","underlying_shares":4805},"source":{"system":"sec-edgar","filing":"0001765581-19-000074","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558119000074/edgardoc.xml","form_type":"4"}},{"id":3441295,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-08-12T21:32:47.000Z","date":"2019-08-09","kind":"sale","acquired":false,"shares":726,"price":135.6497,"value":98481.6822,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.60 to $135.65. The price reported reflects the weighted\naverage sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":7685,"source":{"system":"sec-edgar","filing":"0001765581-19-000074","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558119000074/edgardoc.xml","form_type":"4"}},{"id":3441294,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-08-12T21:32:47.000Z","date":"2019-08-08","kind":"grant","acquired":true,"shares":1920,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 1, 2020."}],"balance_after":8411,"source":{"system":"sec-edgar","filing":"0001765581-19-000074","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000176558119000074/edgardoc.xml","form_type":"4"}},{"id":3521441,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2019-05-17T23:01:48.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":380000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest on May 16, 2021, subject to the Reporting Person's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest on May 16, 2021, subject to the Reporting Person's continued service."}],"balance_after":380000,"derivative":{"underlying":"Common Stock","underlying_shares":380000},"source":{"system":"sec-edgar","filing":"0001104659-19-030348","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000110465919030348/a4.xml","form_type":"4"}},{"id":3604469,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-03-08T21:35:00.000Z","date":"2019-02-20","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 20, 2020."}],"balance_after":12500,"derivative":{"exercise_price":7.31,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-018122","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000120919119018122/doc4.xml","form_type":"4"}},{"id":3702133,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-07T21:26:36.000Z","date":"2019-01-04","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest 25% on January 4, 2020, with the remaining 75% vesting in equal monthly installments over 36 months."}],"balance_after":275000,"derivative":{"exercise_price":19.33,"expiration_date":"2029-01-03","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001104659-19-001129","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000110465919001129/a4.xml","form_type":"4"}},{"id":3763376,"issuer":{"id":4598,"kind":"organization","name":"Eton Pharmaceuticals, Inc.","symbol":"ETON"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T00:10:54.000Z","date":"2018-11-15","kind":"purchase","acquired":true,"shares":5000,"price":6,"value":30000.0,"ownership":{"direct":true},"balance_after":59745,"source":{"system":"sec-edgar","filing":"0001209191-18-058824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000120919118058824/doc4.xml","form_type":"4"}},{"id":3765252,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-14T21:16:54.000Z","date":"2018-11-12","kind":"exercise","acquired":false,"shares":38563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest 25% on January 19, 2018 and the remaining 75% shall vest in equal monthly installments over 36 months."}],"balance_after":441615,"derivative":{"exercise_price":2.59,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":38563},"source":{"system":"sec-edgar","filing":"0001104659-18-068453","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000110465918068453/a4.xml","form_type":"4"}},{"id":3765251,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2018-11-14T21:16:54.000Z","date":"2018-11-12","kind":"exercise","acquired":true,"shares":38563,"price":2.59,"value":99878.17,"ownership":{"direct":true},"balance_after":362539,"source":{"system":"sec-edgar","filing":"0001104659-18-068453","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000110465918068453/a4.xml","form_type":"4"}},{"id":3809911,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-09-21T20:17:28.000Z","date":"2018-09-20","kind":"grant","acquired":true,"shares":427265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest 25% on September 20, 2019, with the remaining 75% vesting in equal monthly installments over 36 months."}],"balance_after":427265,"derivative":{"exercise_price":27.43,"expiration_date":"2028-09-19","underlying":"Common Stock","underlying_shares":427265},"source":{"system":"sec-edgar","filing":"0001104659-18-058017","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000110465918058017/a4.xml","form_type":"4"}},{"id":3846314,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-08-13T23:57:11.000Z","date":"2018-08-09","kind":"grant","acquired":true,"shares":3735,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan.  Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan.  Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018."}],"balance_after":3735,"derivative":{"exercise_price":177.73,"expiration_date":"2028-08-08","underlying":"Ordinary Shares","underlying_shares":3735},"source":{"system":"sec-edgar","filing":"0001232524-18-000160","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000123252418000160/edgardoc.xml","form_type":"4"}},{"id":3846313,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-08-13T23:57:11.000Z","date":"2018-08-10","kind":"sale","acquired":false,"shares":660,"price":176.6107,"value":116563.062,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $176.61 to $177.052. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":6491,"source":{"system":"sec-edgar","filing":"0001232524-18-000160","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000123252418000160/edgardoc.xml","form_type":"4"}},{"id":3846312,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-08-13T23:57:11.000Z","date":"2018-08-09","kind":"grant","acquired":true,"shares":1495,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 2, 2019."}],"balance_after":7151,"source":{"system":"sec-edgar","filing":"0001232524-18-000160","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000123252418000160/edgardoc.xml","form_type":"4"}},{"id":3883263,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-06-26T20:44:09.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":836541,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":30324},"source":{"system":"sec-edgar","filing":"0001104659-18-042295","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000110465918042295/a4.xml","form_type":"4"}},{"id":3883262,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2018-06-26T20:44:09.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":1334254,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":48367},"source":{"system":"sec-edgar","filing":"0001104659-18-042295","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000110465918042295/a4.xml","form_type":"4"}},{"id":3883261,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2018-06-26T20:44:09.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":75000,"ownership":{"direct":false,"nature":"By family members"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2718},"source":{"system":"sec-edgar","filing":"0001104659-18-042295","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000110465918042295/a4.xml","form_type":"4"}},{"id":3883260,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2018-06-26T20:44:09.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":1042482,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":37790},"source":{"system":"sec-edgar","filing":"0001104659-18-042295","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000110465918042295/a4.xml","form_type":"4"}},{"id":3883259,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2018-06-26T20:44:09.000Z","date":"2018-06-25","kind":"purchase","acquired":true,"shares":2400,"price":16,"value":38400.0,"ownership":{"direct":false,"nature":"By family members"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On June 25, 2018, certain family members of the Reporting Person collectively purchased 2,400 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering."}],"balance_after":5118,"source":{"system":"sec-edgar","filing":"0001104659-18-042295","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000110465918042295/a4.xml","form_type":"4"}},{"id":3883258,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2018-06-26T20:44:09.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":2718,"ownership":{"direct":false,"nature":"By family members"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."}],"balance_after":2718,"source":{"system":"sec-edgar","filing":"0001104659-18-042295","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000110465918042295/a4.xml","form_type":"4"}},{"id":3883257,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2018-06-26T20:44:09.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":30324,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."}],"balance_after":323976,"source":{"system":"sec-edgar","filing":"0001104659-18-042295","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000110465918042295/a4.xml","form_type":"4"}},{"id":3883256,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2018-06-26T20:44:09.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":48367,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."}],"balance_after":293652,"source":{"system":"sec-edgar","filing":"0001104659-18-042295","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000110465918042295/a4.xml","form_type":"4"}},{"id":3883255,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2018-06-26T20:44:09.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":37790,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."}],"balance_after":245285,"source":{"system":"sec-edgar","filing":"0001104659-18-042295","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000110465918042295/a4.xml","form_type":"4"}},{"id":4235444,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-08-14T21:27:06.000Z","date":"2017-08-10","kind":"grant","acquired":true,"shares":3415,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan.  Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan.  Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017."}],"balance_after":3415,"derivative":{"exercise_price":143.66,"expiration_date":"2027-08-09","underlying":"Ordinary Shares","underlying_shares":3415},"source":{"system":"sec-edgar","filing":"0001232524-17-000148","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000123252417000148/edgardoc.xml","form_type":"4"}},{"id":4235443,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2017-08-14T21:27:06.000Z","date":"2017-08-11","kind":"sale","acquired":false,"shares":3,"price":144.1307,"value":432.3921,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."}],"balance_after":5656,"source":{"system":"sec-edgar","filing":"0001232524-17-000148","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000123252417000148/edgardoc.xml","form_type":"4"}},{"id":4235442,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2017-08-14T21:27:06.000Z","date":"2017-08-11","kind":"sale","acquired":false,"shares":659,"price":142.36,"value":93815.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."}],"balance_after":5659,"source":{"system":"sec-edgar","filing":"0001232524-17-000148","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000123252417000148/edgardoc.xml","form_type":"4"}},{"id":4235441,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2017-08-14T21:27:06.000Z","date":"2017-08-10","kind":"grant","acquired":true,"shares":1365,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018."},{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018."}],"balance_after":6318,"source":{"system":"sec-edgar","filing":"0001232524-17-000148","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1161662/000123252417000148/edgardoc.xml","form_type":"4"}},{"id":4443840,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-16T14:16:08.000Z","date":"2017-02-16","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."}],"balance_after":0,"derivative":{"exercise_price":23.82,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000884731-17-000053","document":"wf-form4_148727255357743.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000053/wf-form4_148727255357743.xml","form_type":"4"}},{"id":4443839,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-16T14:16:08.000Z","date":"2017-02-16","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."}],"balance_after":0,"derivative":{"exercise_price":4.91,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000884731-17-000053","document":"wf-form4_148727255357743.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000053/wf-form4_148727255357743.xml","form_type":"4"}},{"id":4443838,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-16T14:16:08.000Z","date":"2017-02-16","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."}],"balance_after":0,"derivative":{"exercise_price":6.45,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000884731-17-000053","document":"wf-form4_148727255357743.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000053/wf-form4_148727255357743.xml","form_type":"4"}},{"id":4443837,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-16T14:16:08.000Z","date":"2017-02-16","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."}],"balance_after":0,"derivative":{"exercise_price":7.39,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000884731-17-000053","document":"wf-form4_148727255357743.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000053/wf-form4_148727255357743.xml","form_type":"4"}},{"id":4443836,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-16T14:16:08.000Z","date":"2017-02-16","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."}],"balance_after":0,"derivative":{"exercise_price":8.5,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000884731-17-000053","document":"wf-form4_148727255357743.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000053/wf-form4_148727255357743.xml","form_type":"4"}},{"id":4443835,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-16T14:16:08.000Z","date":"2017-02-16","kind":"disposition_to_issuer","acquired":false,"shares":139867,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the \"Merger Agreement\"), between the Company, Takeda Pharmaceutical Company Limited (\"Takeda\") and Kiku Merger Co., Inc. (\"Purchaser\"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a \"Share\") was converted into the right to receive $24.00 in cash."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a \"Restricted Share\") and 12,500 Shares underlying unvested restricted stock units (each, an \"RSU\"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000884731-17-000053","document":"wf-form4_148727255357743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000053/wf-form4_148727255357743.xml","form_type":"4"}},{"id":4474230,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":903,"kind":"person","name":"RIEDEL NORBERT G","position":1,"cik":"0001161662","reported_name":"RIEDEL NORBERT G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-02-01T16:55:25.000Z","date":"2017-01-31","kind":"grant","acquired":true,"shares":25000,"price":23.82,"value":595500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options granted under our 2014 Long-Term Incentive Plan, as amended, and in accordance with our director compensation policy vest as to approximately one-fourth of the shares underlying the options on the last business day of each calendar quarter in 2017, subject to the terms of the award."}],"balance_after":25000,"derivative":{"exercise_price":23.82,"expiration_date":"2027-01-31","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000884731-17-000011","document":"wf-form4_148598610444217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000011/wf-form4_148598610444217.xml","form_type":"4"}}],"next_cursor":"2017-02-01T16:55:25.000000Z,4474230"}